Cefepime trough levels and clinical outcomes in patients undergoing universal therapeutic drug monitoring: A prospective cohort studyMia Madeleine Lidén, Angela Huttner, Elodie von Dach et al.|CMI Communications|2024Cited by 4
Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted GraftsYan Beauverd, Yves Chalandon, Sarah Morin et al.|Transplantation and Cellular Therapy|2020Cited by 1
Impact of Different T Cell Depletion Protocols on Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell TransplantationAmandine Pradier, Yves Chalandon, Anne‐Claire Mamez et al.|Blood|2020Cited by 1
The AML EBMT Cytogenetic Risk Score for Acute Myeloid Leukaemia (AML) Is Prognostic for Outcomes of Allogeneic Stem Cell (HSCT)Yan Beauverd, Yves Chalandon, Sarah Morin et al.|Blood|2020Cited by 0